Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.

Tytuł:
Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.
Autorzy:
Liu J; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China.; Department of Global Health, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China.; Department of Health Policy, Health Management College, Harbin Medical University, Harbin, Heilongjiang Province, PR China.; Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, PR China.
Wu Q; Department of Health Policy, Health Management College, Harbin Medical University, Harbin, Heilongjiang Province, PR China.; Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, PR China.
Hao Y; Department of Health Policy, Health Management College, Harbin Medical University, Harbin, Heilongjiang Province, PR China.; Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, PR China.
Jiao M; Department of Health Policy, Health Management College, Harbin Medical University, Harbin, Heilongjiang Province, PR China.; Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, PR China.
Wang X; Department of Health Policy, Health Management College, Harbin Medical University, Harbin, Heilongjiang Province, PR China.; Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, PR China.
Jiang S; Department of Health Policy, Health Management College, Harbin Medical University, Harbin, Heilongjiang Province, PR China.; Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang Province, PR China.
Han L; Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China.; Department of Global Health, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China.
Źródło:
Human reproduction (Oxford, England) [Hum Reprod] 2021 Mar 18; Vol. 36 (4), pp. 1108-1119.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Oxford, UK : Oxford University Press
Original Publication: Oxford ; Washington, DC : Published for the European Society of Human Reproduction and Embryology by IRL Press, [c1986-
MeSH Terms:
Global Burden of Disease*
Polycystic Ovary Syndrome*/epidemiology
Adolescent ; Adult ; Brazil ; China ; Female ; Global Health ; Humans ; Incidence ; Japan ; Middle Aged ; Quality-Adjusted Life Years ; Young Adult
References:
Hum Reprod. 2007 Apr;22(4):1011-6. (PMID: 17166864)
J Sex Med. 2011 Jun;8(6):1686-93. (PMID: 21477021)
Steroids. 2012 Mar 10;77(4):295-9. (PMID: 22197663)
Health Care Women Int. 2018 May;39(5):522-535. (PMID: 29313760)
Fertil Steril. 2004 Jan;81(1):19-25. (PMID: 14711538)
Global Health. 2020 Jul 3;16(1):56. (PMID: 32620141)
Indian J Exp Biol. 2003 Jul;41(7):694-700. (PMID: 15255372)
Horm Res Paediatr. 2015 Apr 1;:. (PMID: 25833060)
Ann Endocrinol (Paris). 2014 Sep;75(4):194-9. (PMID: 25156132)
Niger J Clin Pract. 2015 Dec;18 Suppl:S31-9. (PMID: 26620620)
Eur J Endocrinol. 2014 Oct;171(4):489-98. (PMID: 25049203)
J Agromedicine. 2020 Mar 17;:1-12. (PMID: 32182198)
Clin Endocrinol (Oxf). 2018 Sep;89(3):251-268. (PMID: 30024653)
Nat Rev Endocrinol. 2018 May;14(5):270-284. (PMID: 29569621)
Seishin Shinkeigaku Zasshi. 2014;116(4):323-31. (PMID: 24864567)
BMC Pregnancy Childbirth. 2018 Sep 24;18(Suppl 1):373. (PMID: 30255789)
PLoS One. 2014 Mar 25;9(3):e92752. (PMID: 24667658)
Lancet Public Health. 2019 Sep;4(9):e447. (PMID: 31493840)
Pediatr Res. 2020 Jan;87(2):353-361. (PMID: 31627209)
Hum Reprod. 2012 Oct;27(10):3067-73. (PMID: 22777527)
Cad Saude Publica. 2015 Nov;31(11):2331-41. (PMID: 26840813)
Lancet. 2018 Nov 10;392(10159):1789-1858. (PMID: 30496104)
Trends Endocrinol Metab. 1998 Feb;9(2):58-61. (PMID: 18406242)
Oncotarget. 2017 Jul 12;8(56):96351-96358. (PMID: 29221211)
Endocr Rev. 1995 Jun;16(3):322-53. (PMID: 7671850)
Hum Resour Health. 2017 Dec 1;15(1):80. (PMID: 29191247)
Circulation. 2020 May 26;141(21):1670-1680. (PMID: 32223336)
J Public Health Policy. 2017 May;38(2):221-233. (PMID: 28242874)
BMC Med. 2020 Mar 24;18(1):72. (PMID: 32204714)
Hum Reprod Update. 2016 Nov;22(6):687-708. (PMID: 27511809)
Ig Sanita Pubbl. 2019 May-Jun;75(3):189-199. (PMID: 31645061)
J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92. (PMID: 24151290)
Fertil Steril. 2016 Jul;106(1):4-5. (PMID: 27238627)
Cien Saude Colet. 2017 Jun;22(6):1881-1893. (PMID: 28614508)
Aging (Albany NY). 2019 Dec 2;11(23):10952-10991. (PMID: 31790362)
Int J Gynaecol Obstet. 2019 Aug;146(2):164-169. (PMID: 31002378)
Int J Environ Res Public Health. 2018 Nov 20;15(11):. (PMID: 30463276)
Hum Reprod. 2010 Feb;25(2):544-51. (PMID: 19910321)
Lancet. 2018 Nov 10;392(10159):1859-1922. (PMID: 30415748)
Hum Reprod Update. 2012 Nov-Dec;18(6):618-37. (PMID: 22767467)
Am J Public Health. 2011 May;101(5):868-74. (PMID: 20724683)
Hum Reprod. 2018 Sep 1;33(9):1602-1618. (PMID: 30052961)
Obstet Gynecol Surv. 1999 Jun;54(6):403-13. (PMID: 10358853)
Curr Opin Pediatr. 2019 Aug;31(4):562-569. (PMID: 31299022)
Soc Sci Med. 2019 Jul;232:374-381. (PMID: 31136888)
Inj Prev. 2020 Oct;26(Supp 1):i36-i45. (PMID: 31857422)
Contributed Indexing:
Keywords: disability-adjusted life-years; global burden of disease; incidence; polycystic ovary syndrome; socio-demographic index
Entry Date(s):
Date Created: 20210127 Date Completed: 20210528 Latest Revision: 20210528
Update Code:
20240105
PubMed Central ID:
PMC7970729
DOI:
10.1093/humrep/deaa371
PMID:
33501984
Czasopismo naukowe
Study Question: What is the current burden of polycystic ovary syndrome (PCOS) at the global, regional, and country-specific levels in 194 countries and territories according to age and socio-demographic index (SDI)?
Summary Answer: Slight increases in age-standardized incidence of PCOS and associated disability-adjusted life-years (DALYs) were evidenced among women of reproductive age (15-49 years) from 2007 to 2017 at the global level, and in most regions and countries.
What Is Known Already: No detailed quantitative estimates of the PCOS incidence and DALYs by age and SDI in these 194 countries and territories have been published previously.
Study Design, Size, Duration: An age- and SDI-stratified systematic analysis of the PCOS incidence and DALYs across 194 countries and territories has been performed.
Participants/materials, Setting, Methods: We used data from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2017 to estimate the total and age-standard PCOS incidence rates and DALYs rates among women of reproductive age in both 2007 and 2017, and the trends in these parameters from 2007 to 2017.
Main Results and the Role of Chance: Globally, women of reproductive age accounted for 1.55 million (95% uncertainty intervals (UIs): 1.19-2.08) incident cases of PCOS and 0.43 million (0.19-0.82) associated DALYs. The global age-standardized PCOS incidence rate among women of reproductive age increased to 82.44 (64.65-100.24) per 100 000 population in 2017, representing an increase of 1.45% (1.43-1.47%) from 2007 to 2017. The rate of age-standardized DALYs increased to 21.96 (12.78-31.15) per 100 000 population in 2017, representing an increase of 1.91% (1.89-1.93%) from 2007 to 2017. Over the study period, the greatest increase in the age-standardized PCOS incidence and DALYs rates were observed in the middle-SDI and high-middle SDI regions, respectively. At the GBD regional level, the highest age-standardized incidence and DALY rates in 2017 were observed in Andean Latin America, whereas the largest percentage increases in both rates from 2007 to 2017 were observed in Tropical Latin America. At the national level, Ecuador, Peru, Bolivia, Japan, and Bermuda had the highest age-standardized incidence rates and DALYs rates in both 2007 and 2017. The highest increases in both the age-standardized incidence rates and DALYs rates from 2007 to 2017 were observed in Ethiopia, Brazil, and China.
Limitations, Reasons for Caution: Although the GBD (2017) study aimed to gather all published and unpublished data, the limited availability of data in some regions might have led to the estimation of wide UIs. Additionally, the PCOS phenotype is complicated and the diagnostic criteria are constantly changing. Consequently, the incidence of PCOS might have been underestimated.
Wider Implications of the Findings: Knowledge about the differences in the PCOS burden across various locations will be valuable for the allocation of resources and formulation of effective preventive strategies.
Study Funding/competing Interest(s): The study was supported by grants from the Innovative Talent Support Plan of the Medical and Health Technology Project in Zhejiang Province (2021422878), Ningbo Science and Technology Project (202002N3152), Ningbo Health Branding Subject Fund (PPXK2018-02), Sanming Project of Medicine in Shen-zhen (SZSM201803080), and National Social Science Foundation (19AZD013). No potential conflicts of interest relevant to this article were reported.
Trial Registration Number: N/A.
(© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies